These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30348947)

  • 1. Prognostic role of DOK family adapters in acute myeloid leukemia.
    Zhang L; Li R; Hu K; Dai Y; Pang Y; Jiao Y; Liu Y; Cui L; Shi J; Cheng Z; Fu L
    Cancer Gene Ther; 2019 Sep; 26(9-10):305-312. PubMed ID: 30348947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of Wnt and Fzd gene families in acute myeloid leukaemia.
    Dai Y; Cheng Z; Fricke DR; Zhao H; Huang W; Zhong Q; Zhu P; Zhang W; Wu Z; Lin Q; Zhu H; Liu Y; Qian T; Fu L; Cui L; Zeng T
    J Cell Mol Med; 2021 Feb; 25(3):1456-1467. PubMed ID: 33417298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the FUT family in acute myeloid leukemia.
    Dai Y; Cheng Z; Pang Y; Jiao Y; Qian T; Quan L; Cui L; Liu Y; Si C; Chen J; Ye X; Chen J; Shi J; Wu D; Zhang X; Fu L
    Cancer Gene Ther; 2020 Feb; 27(1-2):70-80. PubMed ID: 31209266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of PAK family kinases in acute myeloid leukemia.
    Quan L; Cheng Z; Dai Y; Jiao Y; Shi J; Fu L
    Cancer Gene Ther; 2020 Feb; 27(1-2):30-37. PubMed ID: 30890765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia.
    Liu Y; Lu R; Cui W; Pang Y; Liu C; Cui L; Qian T; Quan L; Dai Y; Jiao Y; Pan Y; Ye X; Shi J; Cheng Z; Fu L
    Cancer Gene Ther; 2020 Feb; 27(1-2):38-44. PubMed ID: 30923336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.
    He PF; Xu ZJ; Zhou JD; Li XX; Zhang W; Wu DH; Zhang ZH; Lian XY; Yao XY; Deng ZQ; Lin J; Qian J
    J Cell Physiol; 2018 Sep; 233(9):6604-6614. PubMed ID: 29150948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of
    Cui W; Liu Y; Tan Y; Peng X; Cui L; Cheng Z; Dai Y; Fu L; Zeng T; Liu Y
    Future Oncol; 2021 Feb; 17(5):541-548. PubMed ID: 33467898
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of A-kinase interacting protein 1 as a potential biomarker for risk and prognosis of acute myeloid leukemia.
    Yan Y; Li X; Gao J
    J Clin Lab Anal; 2020 May; 34(5):e23055. PubMed ID: 32356617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Liu Y; Cui L; Quan L; Qian T; Zeng T; Si C; Huang W; Chen J; Pang Y; Ye X; Shi J; Fu L
    J Cell Mol Med; 2020 Jan; 24(1):1067-1075. PubMed ID: 31755224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High
    Cheng Z; Dai Y; Pang Y; Jiao Y; Liu Y; Cui L; Qian T; Quan L; Cui W; Pan Y; Ye X; Shi J; Fu L
    Cancer Biol Ther; 2019; 20(10):1314-1318. PubMed ID: 31306053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia.
    Cui L; Cheng Z; Liu Y; Dai Y; Pang Y; Jiao Y; Ke X; Cui W; Zhang Q; Shi J; Fu L
    Cancer Gene Ther; 2020 Feb; 27(1-2):15-21. PubMed ID: 30578412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression levels of SMAD3 and SMAD7 at diagnosis predict poor prognosis in acute myeloid leukemia patients undergoing chemotherapy.
    Zhang J; Zhang L; Cui H; Zhang X; Zhang G; Yang X; Yang S; Zhang Z; Wang J; Hu K; Shi J; Ke X; Fu L
    Cancer Gene Ther; 2019 May; 26(5-6):119-127. PubMed ID: 30177817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy.
    Yang C; Shao T; Zhang H; Zhang N; Shi X; Liu X; Yao Y; Xu L; Zhu S; Cao J; Cheng H; Yan Z; Li Z; Niu M; Xu K
    J Transl Med; 2018 Oct; 16(1):267. PubMed ID: 30285885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
    Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of AK1 predicts inferior prognosis in acute myeloid leukemia patients undergoing chemotherapy.
    Qin T; Zhao H; Shao Y; Hu N; Shi J; Fu L; Zhang Y
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32519744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of SCAMP family in acute myeloid leukemia.
    Qian T; Cheng Z; Quan L; Zeng T; Cui L; Liu Y; Si C; Huang W; Dai Y; Chen J; Liu L; Jiao Y; Deng C; Pang Y; Ye X; Shi J; Fu L
    Pharmacogenomics J; 2020 Aug; 20(4):595-600. PubMed ID: 31988488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.
    Sun GK; Tang LJ; Zhou JD; Xu ZJ; Yang L; Yuan Q; Ma JC; Liu XH; Lin J; Qian J; Yao DM
    Cancer Med; 2019 Oct; 8(14):6393-6402. PubMed ID: 31486300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.